杜瓦卢马布
阶段(地层学)
医学
放射治疗
化疗
肿瘤科
放射科
内科学
癌症
免疫疗法
生物
无容量
古生物学
作者
Andrea Riccardo Filippi,M.R. García Campelo,J-B. Paoli,D. Kowalski,Chiara Bennati,P. Borghetti,Diego Luigi Cortinovis,Angelo Delmonte,C. Genova,R. Mroz,Sergiusz Nawrocki,Ivan Toledano,Giuseppe Tonini,Francesco Agustoni,G. Wetherill,Ignacio Diaz Perez,Nefeli Georgoulia,Rafał Dziadziuszko
标识
DOI:10.1016/j.iotech.2024.100809
摘要
Currently, pts with unresectable Stage III NSCLC ineligible for CT receive RT alone, with unsatisfactory outcomes. Results from an interim analysis of DUART (NCT04249362) showed that RT followed by durvalumab was well tolerated in this older, frailer population. Importantly, preliminary efficacy data were encouraging. Here we report the final analysis, including updated PFS and OS after longer follow-up.
科研通智能强力驱动
Strongly Powered by AbleSci AI